MAXIMIZE MEDICAL MANAGEMENT OF XHANCE

When patients remain symptomatic after standard intranasal corticosteroid sprays, choose XHANCE next in a stepped-care approach to treat nasal polyps1

The “Multidisciplinary Consensus on a Stepwise Treatment Algorithm for Management of Chronic Rhinosinusitis With Nasal Polyps” includes EDS-FLU, marketed as XHANCE, as a treatment option distinct from standard intranasal corticosteroid sprays.1

Important Information: This publication was not funded by Optinose. Some of the authors have been separately engaged by Optinose for clinical research, consulting, or speaking.

See where XHANCE is recommended as an option in the treatment algorithm

SELECT PATIENT STATUS:

  1. My patient has symptoms consistent with nasal polyps
  2. My patient may need escalation of treatment
  3. See full algorithm





*Evaluate for bilateral vs unilateral to rule out neoplasm.

AERD=aspirin-exacerbated respiratory disease; ASA=acetylsalicylic acid (aspirin); CBC=complete blood count; CT=computerized tomography scan; EDS-FLU=exhalation delivery system with fluticasone; IgE=immunoglobulin E; INS=intranasal steroids; OCS=oral corticosteroids; QoL=quality of life

AERD=aspirin-exacerbated respiratory disease; ASA=acetylsalicylic acid (aspirin); EDS-FLU=exhalation delivery system with fluticasone; INS=intranasal steroids; OCS=oral corticosteroids.
*Evaluate for bilateral vs unilateral to rule out neoplasm.

AERD=aspirin-exacerbated respiratory disease; ASA=acetylsalicylic acid (aspirin); CBC=complete blood count; CT=computerized tomography scan; EDS-FLU=exhalation delivery system with fluticasone; IgE=immunoglobulin E; INS=intranasal steroids; OCS=oral corticosteroids; QoL=quality of life.


Adapted by Optinose from: Han, JK, Bosso, JV, Cho, SH, et al. Multidisciplinary consensus on a stepwise treatment algorithm for management of chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2021; 1–10.
If patients are refractory, please advance to next section (button above)
The full article in the International Forum of Allergy & Rhinology, is open access and can be read here.